AU745094B2 - Solid phase native chemical ligation of unprotected or N-terminal cysteine protected peptides in aqueous solution - Google Patents

Solid phase native chemical ligation of unprotected or N-terminal cysteine protected peptides in aqueous solution Download PDF

Info

Publication number
AU745094B2
AU745094B2 AU80695/98A AU8069598A AU745094B2 AU 745094 B2 AU745094 B2 AU 745094B2 AU 80695/98 A AU80695/98 A AU 80695/98A AU 8069598 A AU8069598 A AU 8069598A AU 745094 B2 AU745094 B2 AU 745094B2
Authority
AU
Australia
Prior art keywords
peptide
solid phase
terminal
bound
unprotected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU80695/98A
Other languages
English (en)
Other versions
AU8069598A (en
Inventor
Lynne Canne
Stephen B.H. Kent
Reyna Simon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gryphon Therapeutics Inc
Original Assignee
Gryphon Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gryphon Sciences filed Critical Gryphon Sciences
Publication of AU8069598A publication Critical patent/AU8069598A/en
Application granted granted Critical
Publication of AU745094B2 publication Critical patent/AU745094B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • C07K1/086General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents containing sulfur
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/023General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution using racemisation inhibiting agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/026General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047Simultaneous synthesis of different peptide species; Peptide libraries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
AU80695/98A 1997-06-13 1998-06-12 Solid phase native chemical ligation of unprotected or N-terminal cysteine protected peptides in aqueous solution Ceased AU745094B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4955397P 1997-06-13 1997-06-13
US60/049553 1997-06-13
PCT/US1998/012278 WO1998056807A1 (en) 1997-06-13 1998-06-12 Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution

Publications (2)

Publication Number Publication Date
AU8069598A AU8069598A (en) 1998-12-30
AU745094B2 true AU745094B2 (en) 2002-03-14

Family

ID=21960431

Family Applications (1)

Application Number Title Priority Date Filing Date
AU80695/98A Ceased AU745094B2 (en) 1997-06-13 1998-06-12 Solid phase native chemical ligation of unprotected or N-terminal cysteine protected peptides in aqueous solution

Country Status (9)

Country Link
US (4) US6326468B1 (enExample)
EP (1) EP1001968B1 (enExample)
JP (1) JP2002505672A (enExample)
AT (2) ATE285415T1 (enExample)
AU (1) AU745094B2 (enExample)
CA (1) CA2292724A1 (enExample)
DE (2) DE69837170T2 (enExample)
ES (2) ES2235336T3 (enExample)
WO (1) WO1998056807A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184344B1 (en) * 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US6849428B1 (en) * 1997-03-05 2005-02-01 New England Biolabs, Inc. Intein-mediated protein ligation of expressed proteins
DE69837170T2 (de) * 1997-06-13 2007-11-22 Amylin Pharmaceuticals, Inc., San Diego Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen
CA2301846A1 (en) 1997-09-04 1999-03-11 Gryphon Sciences Modular protein libraries and methods of preparation
AUPP589598A0 (en) 1998-09-14 1998-10-08 University Of Queensland, The Novel peptides
US7001745B1 (en) * 1998-09-30 2006-02-21 New England Biolabs, Inc. Intein mediated peptide ligation
WO2000053624A1 (en) * 1999-03-11 2000-09-14 Gryphon Sciences Chemical synthesis and use of soluble membrane protein receptor domains
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US20040014082A1 (en) * 2000-08-11 2004-01-22 Invitrogen Corporation Highly homogeneous molecular markers for electrophoresis
WO2002013848A1 (en) * 2000-08-11 2002-02-21 Invitrogen Corporation Highly homogeneous molecular markers for electrophoresis
WO2002018417A1 (en) * 2000-09-01 2002-03-07 Gryphon Therapeutics, Inc. Nucleophile-stable thioester generating compounds, methods of production and use
EP1353941B1 (en) * 2001-01-22 2013-03-13 Sangamo BioSciences, Inc. Modified zinc finger binding proteins
JP4408628B2 (ja) * 2001-03-09 2010-02-03 ボストン プローブス,インコーポレイテッド 組み合わせオリゴマーならびにそれらの調製のためのライブラリーに適する、方法、キット、および組成物
GB0113657D0 (en) * 2001-06-05 2001-07-25 Geneprot Inc Improved native chemical ligation with three or more components
ES2561985T3 (es) 2001-10-10 2016-03-01 Ratiopharm Gmbh Remodelación y glicoconjugación de anticuerpos
US7781488B2 (en) * 2002-06-10 2010-08-24 Amylin Pharmaceuticals, Inc. Post-cleavage sulfur deprotection for convergent protein synthesis by chemical ligation
ES2254725T3 (es) * 2002-06-29 2006-06-16 Aquanova German Solubilisate Technologies (Agt) Gmbh Concentrados de isoflavonas y metodos para su preparacion.
US7981862B2 (en) 2003-08-19 2011-07-19 Biosurface Engineering Technologies, Inc. Composition comprising BMP-2 amplifier/co-activator for enhancement of osteogenesis
US7598224B2 (en) * 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US7166574B2 (en) * 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US8227411B2 (en) 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
US7482427B2 (en) * 2002-08-20 2009-01-27 Biosurface Engineering Technologies, Inc. Positive modulator of bone morphogenic protein-2
AU2003300859A1 (en) * 2002-12-11 2004-06-30 New England Biolabs, Inc. Carrier-ligand fusions and uses thereof
EP1616003A4 (en) 2002-12-30 2007-06-20 Gryphon Therapeutics Inc WATER-SOLUBLE THIOESTER AND SELENOESTER COMPOUNDS AND METHOD FOR THE PRODUCTION AND USE THEREOF
EP2055189A1 (en) 2003-04-09 2009-05-06 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ES2558102T3 (es) * 2003-05-06 2016-02-02 Biogen Hemophilia Inc. Proteínas quiméricas del factor de coagulación para el tratamiento de un trastorno hemostático
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
EP1631597A4 (en) * 2003-05-22 2007-07-11 Gryphon Therapeutics Inc SOLID PHASE CHEMICAL LIGATION CARRIED OUT WITH A MOBILE BONDING AGENT
US7414028B1 (en) * 2004-02-04 2008-08-19 Biosurface Engineering Technologies, Inc. Growth factor analogs
US20060024347A1 (en) * 2004-02-10 2006-02-02 Biosurface Engineering Technologies, Inc. Bioactive peptide coatings
US20080227696A1 (en) 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
US7671012B2 (en) 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
US7528105B1 (en) 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
CA2563502A1 (en) 2004-04-09 2005-10-20 Chugai Seiyaku Kabushiki Kaisha Novel water-soluble prodrug
EP1749022A2 (en) * 2004-05-24 2007-02-07 Rigel Pharmaceuticals, Inc. Methods for cyclizing synthetic polymers
US7671023B2 (en) 2005-03-31 2010-03-02 Amylin Pharmaceuticals, Inc. Amylin agonist for treating depression, anxiety disorder and schizophrenia
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
WO2007100358A2 (en) * 2005-10-07 2007-09-07 University Of Chicago Convergent synthesis of proteins by kinetically controlled ligation
US20090118271A1 (en) * 2005-10-19 2009-05-07 Chugai Seiyaku Kabushiki Kaisha Preventive or Therapeutic Agents for Pancreatic Cancer, Ovarian Cancer, or Liver Cancer Comprising a Novel Water-Soluble Prodrug
US7820172B1 (en) 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
WO2008097536A2 (en) 2007-02-05 2008-08-14 Amylin Pharmaceuticals, Inc. Compositions and methods for treating psychiatric diseases and disorders
WO2009032133A2 (en) * 2007-08-28 2009-03-12 Ipsen Pharma S.A.S. Methods and intermediates for chemical synthesis of polypeptides and proteins
EP2536287A4 (en) * 2010-02-18 2015-10-07 Advanced Proteome Therapeutics Inc SPECIFIC SITE SIZE OF PROTEINS USING CHEMICAL MODIFICATION TO PROMOTE PROTEIN CONJUGATE FORMATION, PROTEIN DIMER FORMATION, AND AGRAFTED PEPTIDES
BR112013007442A2 (pt) 2010-09-28 2019-09-24 Amylin Pharmaceuticals Llc polipeptídeos construídos tendo duração de ação realçada
BR112013007385B1 (pt) 2010-09-28 2022-07-26 Amylin Pharmaceuticals, Llc Polipeptídeo quimérico, seu uso e composição que o compreende
WO2013009545A1 (en) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action with reduced immunogenicity
ES2732475T3 (es) 2011-07-08 2019-11-22 Aegerion Pharmaceuticals Inc Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida
FR2981352B1 (fr) * 2011-10-17 2015-07-03 Centre Nat Rech Scient Procede de synthese de proteines
JP6290187B2 (ja) 2012-05-11 2018-03-07 クランツ,アレクサンダー 癌の処置のためのタンパク質の部位特異的標識及び標的送達
EP2852619A4 (en) 2012-05-21 2016-04-27 Massachusetts Inst Technology TRANSLOCATION OF NON-NATURAL CHEMICALS BY MILZBRAND PROTECTIVE ANTIGENPORES
SG10201707600XA (en) 2013-03-15 2017-11-29 Biogen Ma Inc Factor ix polypeptide formulations
WO2017151939A1 (en) * 2016-03-02 2017-09-08 The Brigham And Women's Hospital, Inc. Use of pla2g5-deficient suppressive macrophages in suppression of inflammation
RU2757050C2 (ru) * 2017-03-02 2021-10-11 Глитек, Инк. Способ получения аминокислотного полимера
WO2020070587A1 (en) 2018-10-01 2020-04-09 Université De Genève Methods for producing a plurality of polypeptide variants suitable for biological analysis
WO2020110330A1 (ja) * 2018-11-30 2020-06-04 株式会社糖鎖工学研究所 ペプチドチオエステル、ペプチドの新規製造方法
GB2604481A (en) 2019-10-10 2022-09-07 1859 Inc Methods and systems for microfluidic screening
EP3838913A4 (en) * 2019-10-23 2021-11-03 MabPlex International Co., Ltd. OLIGOPEPTIDE LINKER INTERMEDIATE AND MANUFACTURING PROCESS FOR IT
WO2022266467A2 (en) 2021-06-17 2022-12-22 Dana-Farber Cancer Institute, Inc. Recombinant histone polypeptide and uses thereof
EP4646232A1 (en) 2023-01-06 2025-11-12 Université de Genève Variant ligand conjugates for payload delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064940A (en) * 1988-05-11 1991-11-12 Protein Technologies, Inc. Premixed dry reagent containing a protected amino acid and an activating agent for use in solid phase protein synthesis
US5101059A (en) * 1989-12-05 1992-03-31 Research Corporation Technologies, Inc. Amino acid protecting groups
DE69521815T2 (de) 1995-05-04 2002-04-04 The Scripps Research Institute, La Jolla Proteinsynthese mittels nativer chemischer ligation (07.01.97)
CA2273071C (en) 1996-12-24 2008-07-29 The Scripps Research Institute Method for ligating oligopeptides
DE69837170T2 (de) * 1997-06-13 2007-11-22 Amylin Pharmaceuticals, Inc., San Diego Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen
US6329468B1 (en) * 2000-01-21 2001-12-11 Bostik Findley, Inc. Hot melt adhesive based on semicrystalline flexible polyolefins

Also Published As

Publication number Publication date
US20020132975A1 (en) 2002-09-19
JP2002505672A (ja) 2002-02-19
DE69828287D1 (de) 2005-01-27
AU8069598A (en) 1998-12-30
DE69828287T2 (de) 2005-12-15
EP1001968B1 (en) 2004-12-22
ES2282788T3 (es) 2007-10-16
US6326468B1 (en) 2001-12-04
US20020169282A1 (en) 2002-11-14
WO1998056807A1 (en) 1998-12-17
EP1001968A1 (en) 2000-05-24
US7030217B2 (en) 2006-04-18
DE69837170D1 (de) 2007-04-05
CA2292724A1 (en) 1998-12-17
ATE354584T1 (de) 2007-03-15
ATE285415T1 (de) 2005-01-15
US20050209440A1 (en) 2005-09-22
US7094871B2 (en) 2006-08-22
ES2235336T3 (es) 2005-07-01
DE69837170T2 (de) 2007-11-22

Similar Documents

Publication Publication Date Title
AU745094B2 (en) Solid phase native chemical ligation of unprotected or N-terminal cysteine protected peptides in aqueous solution
Raibaut et al. Solid phase protein chemical synthesis
US7718598B1 (en) Auxiliary for amide bond formation
EP1392718B1 (en) Improved native chemical ligation with three or more components
CA2273071C (en) Method for ligating oligopeptides
Marinzi et al. A new scaffold for amide ligation
CZ80399A3 (cs) Způsob výroby peptidů
JP2002533299A (ja) 環状ペプチドの合成
US20080039612A1 (en) Attachment and elaboration strategies for inverse peptide synthesis
WO2002094857A1 (en) Inverse solid phase synthesis of peptides
EP1456225A2 (en) Extended native chemical ligation of three or more peptide fragments
EP1518862B1 (en) Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution
RU2043362C1 (ru) Способ твердофазного синтеза пептидов
AU4862801A (en) Purification of polypeptides
RU2777327C1 (ru) Способ синтеза пептидов
AU2019414977B2 (en) Method for synthesising peptides
CA2036657C (en) Temporary minimal protection synthesis of lh-rh analogs
AU768649B2 (en) Auxiliary for amide bond formation
CN114008066A (zh) 肽或蛋白质或拟肽的制造方法
AU2002363612A1 (en) Extended native chemical ligation of three or more peptide fragments

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)